AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 797515
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of nickel (double-blind test)
Trial: 31175814
Drug: Passive Music
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive Music Therapy (MT)
Trial: 21289017
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium infusion (20‐mmol (5 g) magnesium sulfate for 5 consecutive days)
Trial: 17202010
Drug: Dextromethorphan 30
RxNorm normalized name: DEXTROMETHORPHAN 30MG/5ML LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan 30 mg (n = 25)
Trial: 11524307
Drug: Acamprosate (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acamprosate (two 333 mg tablets given three times daily for 180 days)
Trial: 9773133
Drug: Triple epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple epidural mixture with adrenaline (bupivacaine 1 mg/ml, fentanyl 2 micrograms/ml, adrenaline 2 micrograms/ml)
Trial: 9773133
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion without adrenaline
Trial: 7824963
Drug: Native heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native heparin
Trial: 1015603
Drug: Pethidine 150
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 150 mg intramuscularly
Trial: 21746944
Drug: Posaconazole 100
RxNorm normalized name: posaconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole 100 mg QD for 24 weeks
Trial: 21746944
Drug: Posaconazole 200
RxNorm normalized name: posaconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole 200 mg QD for 24 weeks
Trial: 21746944
Drug: Posaconazole 400
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 400 mg QD for 24 weeks
Trial: 21746944
Drug: Posaconazole 400
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 400 mg QD for 12 weeks
Trial: 19505307
Drug: Non-hormone therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-hormone therapy (non-HT)
Trial: 9388905
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vaccine (5 mg rBS and 10^8 WC)
Trial: 9388905
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose vaccine (1 mg rBS and 10^8 WC)
Trial: 1414052
Drug: PEG solution
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG solution (Oralav)
Trial: 1414052
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's lactate solution (control group)
Trial: 2578107
Drug: Verapamil (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (150 micrograms/kg intravenous bolus followed by 150 micrograms/kg/hr intravenous infusion)
Trial: 31649376
Drug: Daily mud
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily mud packs and bicarbonate-alkaline mineral water baths
Trial: 31649376
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mud packs and thermal hydrotherapy
Trial: 31649376
Drug: Usual medication
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual medication only
Trial: 30155979
Drug: Ocrelizumab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocrelizumab (600 mg)
Trial: 27325147
Drug: CT-based treatment
RxNorm normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-based treatment (n=92; 46 adrenalectomy, 46 mineralocorticoid receptor antagonist)
Trial: 27325147
Drug: AVS-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVS-based treatment (n=92; 46 adrenalectomy, 46 mineralocorticoid receptor antagonist)
Trial: 27325147
Drug: CT-based treatment
RxNorm normalized name: Ct-053 free base
DrugBank: Ningetinib (DB16256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-based treatment
Trial: 27325147
Drug: AVS-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVS-based treatment
Trial: 22056854
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 every 21 days for four cycles
Trial: 22056854
Drug: Pegylated liposomal
RxNorm normalized name: doxorubicin HCl pegylated liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated liposomal doxorubicin 35 mg/m2 + Cyclophosphamide + Trastuzumab 2 mg/kg weekly for 12 weeks
Trial: 17258146
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg/day) + resistance exercise
Trial: 12042982
Drug: Doxorubicin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (70 mg/m²) plus Ifosfamide (5 g/m²) followed by radiotherapy (chemotherapy arm)
Trial: 12042982
Drug: Etoposide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (250 mg/m²) + Ifosfamide (6 g/m²) + Doxorubicin (50 mg/m²) within 12 weeks (chemotherapy arm)
Trial: 12042982
Drug: Etoposide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (250 mg/m²) + Ifosfamide (6 g/m²) + Doxorubicin (50 mg/m²) combined with regional hyperthermia (RHT + chemotherapy arm)
Trial: 12042982
Drug: Radiotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy alone with no further treatment (observation arm)
Trial: 7814832
Drug: Oral GHBA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GHBA administration
Trial: 7814832
Drug: Oral GHBA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral GHBA and i.v. flumazenil administration
Trial: 7814832
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo and i.v. saline administration
Trial: 2761740
Drug: Defibrotide alone
RxNorm normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Defibrotide alone or in addition to conventional therapies
Trial: 2761740
Drug: Defibrotide with
RxNorm normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Defibrotide with conventional therapies
Trial: 25739031
Drug: Ethinyl-estradiol 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinyl-estradiol 0.03 mg + Drospirenone 3 mg (EE + DRSP)
Trial: 25739031
Drug: Ethinyl-estradiol 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinyl-estradiol 0.03 mg + Chlormadinone acetate 2 mg (EE + CMA)
Trial: 23609610
Drug: 5‐HTP (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐HTP (three 50‐mg capsules)
Trial: 19952467
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (aspirin 100 mg, clopidogrel 75 mg, and triflusal 300 mg per day)
Trial: 19952467
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (aspirin 100 mg and clopidogrel 75 mg per day)
Trial: 10676676
Drug: Garlic treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic treatment (300 mg three times a day for three months)
Trial: 10676676
Drug: Garlic treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic treatment or Placebo in LDL pattern A subjects
Trial: 9377680
Drug: Adjuvant radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant radiotherapy to maximal dose 6000 cGy (group I)
Trial: 26900092
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CCRT) with 66 Gy in 24 fractions and daily low dose cisplatin
Trial: 21915516
Drug: 1.23% acidulated
RxNorm normalized name: Nupro APF 1.23% Acidulated Phosphate Fluoride Gel (Bubblegum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.23% acidulated phosphate fluoride gel, pH 4.1
Trial: 21915516
Drug: 3% potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% potassium oxalate gel, pH 4.1 (Oxa-Gel®)
Trial: 21915516
Drug: iron sulfate
RxNorm normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iron sulfate gel (10 mmol/L FeSO4), pH 4.1
Trial: 19033181
Drug: Intensive recommended
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive recommended treatment and lifestyle advice in cardiovascular prevention (observational design)
Trial: 16556241
Drug: Probable Chronic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probable Chronic Migraine (PCM) and Probable Analgesic-Abuse Headache (PAAH)
Trial: 6111672
Drug: Prostacyclin administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostacyclin administration
Trial: 28651589
Drug: Behavioural Activation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural Activation (BA) delivered by trained mental health nurses, consisting of 8 weekly 30-minute sessions.
Trial: 28651589
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) in primary care.
Trial: 21646576
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus group cognitive behavioral therapy (16 sessions of 2 hours each)
Trial: 15528912
Drug: Toothpaste fluoridation
RxNorm normalized name: sodium fluoride Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpaste fluoridation (SnF2/Olaflur; 0.14% F‐) for 3 x 5 min daily
Trial: 15528912
Drug: Intensive fluoridation
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive fluoridation (Toothpaste + Mouthrinse (SnF2/Olaflur; 0.025% F‐) for 3 x 5 min daily + Gel (NaF/Olaflur, 1.25% F‐) on days 1 and 3)
Trial: 12019102
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% acyclovir-1% hydrocortisone cream (ME-609)
Trial: 7494183
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium controlled-release matrix tablets (various formulations)
Trial: 7494183
Drug: Stability testing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stability testing of diclofenac sodium formulations
Trial: 7494183
Drug: In-vivo study
RxNorm normalized name: Vivotif
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-vivo study of sustained release formulations
Trial: 31157964
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (nonsteroidal antiandrogen therapy)
Trial: 22392179
Drug: Zinc (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (10 mg for 2‐ to 11‐month‐olds and 20 mg for older children)
Trial: 11916282
Drug: Methimazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole (30 mg initial dose for at least 2 months, stopped 6 days before treatment)
Trial: 11916282
Drug: Beta-blocker (atenolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker (atenolol 50-100 mg/d)
Trial: 8522632
Drug: Phenytoin 200
RxNorm normalized name: phenytoin 200 mg oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin 200 mg and 300 mg once daily for 14 weeks
Trial: 2401129
Drug: Diltiazem sustained-release
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diltiazem sustained-release formulation
Trial: 447112
Drug: Rowachol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rowachol (2 capsules, three times a day for 48 hours)
Trial: 447112
Drug: Rowachol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rowachol (1 capsule, three times a day for 48 hours)
Trial: 447112
Drug: Rowachol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rowachol (4 capsules, four times a day for 48 hours)
Trial: 24256450
Drug: Paracetamol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol + placebo diclofenac
Trial: 24256450
Drug: Diclofenac +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac + placebo paracetamol
Trial: 24256450
Drug: Paracetamol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol + diclofenac
Trial: 21323785
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5% hydrogen peroxide and sodium hypochlorite with composite resin
Trial: 19674165
Drug: Dutasteride once
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dutasteride once daily for 52 weeks
Trial: 16930852
Drug: D,L‐fenfluramine (FEN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D,L‐fenfluramine (FEN) 60 mg oral after a 7‐day cocaine‐free period
Trial: 16930852
Drug: Cocaine (96
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (96 mg intranasal)
Trial: 16930852
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 mg cocaine)
Trial: 20064249
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (vehicle)
Trial: 15577414
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine gel with neurotoxin exposure
Trial: 15577414
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine gel without neurotoxin exposure
Trial: 11369252
Drug: Cisplatin-based front-line
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based front-line intraperitoneal therapy
Trial: 11369252
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (not specified)
Trial: 9534319
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin 12,500 IU twice daily for 3 months
Trial: 9534319
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin treatment
Trial: 3122278
Drug: Misoprostol 800
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol 800 mcg daily (given as two or four divided doses)
Trial: 3122278
Drug: Cimetidine (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (conventional doses)
Trial: 19501212
Drug: EE/CMA (ethinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/CMA (ethinyl estradiol 0.03 mg and chlormadinone acetate 2 mg)
Trial: 12668792
Drug: Salbutamol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (15 micro g/kg over 20 minutes)
Trial: 12668792
Drug: Aminophylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (5 mg/kg over 20 minutes)
Trial: 30649227
Drug: Lacosamide 200
RxNorm normalized name: lacosamide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide 200 mg BID
Trial: 23313581
Drug: Intranasal vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal vasopressin (AVP) 20 IU
Trial: 20493637
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OT) 24 IU
Trial: 22902348
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg orally once daily starting on cycle day 8 until follicle rupture or onset of next menses)
Trial: 22902348
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg orally once daily starting with LH surge for 6 days)
Trial: 19281728
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg tablet (test formulation)
Trial: 19281728
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg tablet (reference formulation)
Trial: 15679233
Drug: Pristinamycin 1
RxNorm normalized name: pristinamycin
DrugBank: Pristinamycin (DB13704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pristinamycin 1 g bid for 4 days
Trial: 15679233
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 250 mg bid for 5 days
Trial: 3109088
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) starting one week prior to transplant
Trial: 3109088
Drug: Hydration with
RxNorm normalized name: Gold Bond Healing Hydration with Aloe Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration with a 5% dextrose solution containing electrolytes, minerals, trace elements, and vitamins (Control)
Trial: 28891743
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (CG) - Treatment as usual
Trial: 26665571
Drug: Carbetocin 100
RxNorm normalized name: Carbetocin 100 microgram/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin 100 µg i.v.
Trial: 24160333
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) plus intercourse for six cycles
Trial: 24160333
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) plus IUI for six cycles
Trial: 24160333
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CC only)
Trial: 21167339
Drug: Female sex
RxNorm normalized name: ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Female sex associated with a 23% (or 13-minute) increase in time from hospital arrival to reperfusion therapy.
Trial: 12893503
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (16 sessions of Short Psychodynamic Supportive Psychotherapy) and pharmacotherapy (fluoxetine, amitriptyline, and moclobemide)
Trial: 10886311
Drug: Oral high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral high-dose methylprednisolone treatment for 15 days
Trial: 8312196
Drug: Intervention cytoreduction
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention cytoreduction after 3 cycles of chemotherapy
Trial: 8312196
Drug: 3 further
RxNorm normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-54431 Featuring You Hydrating Skin Enhancing Tint SPF30-270 FURTHER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 further cycles of chemotherapy
Trial: 3087701
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition solution supplemented with 44.6% branched-chain amino acids (BCAA)
Trial: 3087701
Drug: Standard total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard total parenteral nutrition (19.0% BCAA)
Trial: 20573926
Drug: Carboplatin-paclitaxel (chemotherapy)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin-paclitaxel (chemotherapy)
Trial: 19088832
Drug: Beta-adrenoceptor blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenoceptor blockers
Trial: 12942401
Drug: Norfloxacin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin, 400 mg twice per day
Trial: 12942401
Drug: Azithromycin, 500
RxNorm normalized name: Azithromycin, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, 500 mg once per day
Trial: 10789592
Drug: IFN-alpha-2a, 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha-2a, 6 MIU s.c. TIW for 4 weeks, followed by 3 MIU s.c. TIW, and 13-cis-retinoic acid 1 mg/kg/day p.o. BID daily
Trial: 10789592
Drug: Trophosphamide 100-150
RxNorm normalized name: cyclophosphamide 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trophosphamide 100-150 mg/day p.o. BID
Trial: 10789592
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance treatment (Control group)
Trial: 8262820
Drug: BFM chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFM chemotherapy with 1800 cGy cranial irradiation